Appointments at Sigma-Aldrich, Novavax and Pfizer’s CEO taking on an additional role – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Medicine Management occupations Corporate governance Ceo

in-PharmaTechnologist presents its latest round up of movements in the pharma space, including appointments at Sigma-Aldrich, Novavax and Pfizer’s CEO taking on an additional role.

George Miller​ has been appointed as senior vice president (VP), general counsel and secretary of Sigma-Aldrich​. Miller has 20 years of corporate legal experience at companies including Novartis and Federal Express Corporation.

Amsterdam Molecular Therapeutics ​(AMT) has appointed Jorn Aldag​ as CEO. From 2001 to 2008 Aldag served as CEO of Evotec and is also chairman of the board of molecular partners in Switzerland.

Novavax ​has appointed Stanley Erck​ to its board’s corporate governance, compensation and finance committees. Erck has previously served as CEO of several vaccine and immunology products companies and joined the Novavax board in June.

Asher Rubin​ has been appointed as executive VP, chief legal officer and secretary of Intrexon​. Rubin has previously worked at Hogan & Hartson, Guilford Pharmaceuticals and has been active in the proceedings of the Biotechnology Industry Organization (BIO).

immatics biotechnologies ​has appointed Carsten Reinhardt​ as chief medical officer. Reinhardt joins immatics from Micromet. He has also worked at Hoffman-La Roche, where he worked on Herceptin (trastuzumab), and held positions at various academic institutions.

George Church​ has been appointed as director of Sigma-Aldrich​. Church is a professor of genetics at Harvard Medical School and has been granted more than 10 US patents.

Pfizer’s CEO Jeff Kindler​ has been elected to the New York Fed​’s board as a class B director. Kindler is serving the unexpired portion of a three-year term ending December 31.

John Kelley ​has resigned as president and chief operating officer of The Medicines Company​. Kelley has left “to pursue other interests​” and will remain as special advisor to the company’s CEO until December 31 at the earliest.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more